Kite Pharma Reports Second Quarter 2016 Financial Results

SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite Pharma, Inc. (Nasdaq: KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous cell therapy (eACTâ„¢) products for the treatment of cancer, today reported financial results for the second quarter 2016 and recent business highlights.

Back to news